Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 November 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 192 pages)

 

Export 30 results:
Author Title Type [ Year(Asc)]
Filters: Author is Currie, C. J.  [Clear All Filters]
2014
C. J. Currie, Berni, E., Jenkins-Jones, S., Poole, C. D., Ouwens, M., Driessen, S., de Voogd, H., Butler, C. C., and Morgan, C. L., Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis, Bmj, vol. 349, p. g5493, 2014.
C. L. Morgan, Mukherjee, J., Jenkins-Jones, S., Holden, S. E., and Currie, C. J., Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study, Diabetes Obes Metab, vol. 16, pp. 957-62, 2014.
C. A. Bannister, Holden, S. E., Jenkins-Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., and Currie, C. J., Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls, Diabetes Obes Metab, vol. 16, pp. 1165-73, 2014.
C. L. Morgan, Mukherjee, J., Jenkins-Jones, S., Holden, S. E., and Currie, C. J., Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality, Diabetes Obes Metab, vol. 16, pp. 977-83, 2014.
C. L. Morgan, Puelles, J., Poole, C. D., and Currie, C. J., The effect of withdrawal of rosiglitazone on treatment pathways, diabetes control and patient outcomes: a retrospective cohort study, J Diabetes Complications, vol. 28, pp. 360-4, 2014.
C. A. Bannister, Poole, C. D., Jenkins-Jones, S., Morgan, C. L., Elwyn, G., Spasic, I., and Currie, C. J., External validation of the UKPDS risk engine in incident type 2 diabetes: a need for new type 2 diabetes-specific risk equations, Diabetes Care, vol. 37, pp. 537-45, 2014.
S. E. Holden, Gale, E. A., Jenkins-Jones, S., and Currie, C. J., How many people inject insulin? UK estimates from 1991 to 2010, Diabetes Obes Metab, vol. 16, pp. 553-9, 2014.
2013
S. H. Holden, Barnett, A. H., Peters, J. R., Jenkins-Jones, S., Poole, C. D., Morgan, C. L., and Currie, C. J., The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010, Diabetes Obes Metab, vol. 15, pp. 844-52, 2013.
C. J. Currie, Poole, C. D., Evans, M., Peters, J. R., and Morgan, C. L., Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes, J Clin Endocrinol Metab, vol. 98, pp. 668-77, 2013.
C. D. Poole, Halcox, J. P., Jenkins-Jones, S., Carr, E. S., Schifflers, M. G., Ray, K. K., and Currie, C. J., Omega-3 Fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study, Clin Ther, vol. 35, pp. 40-51, 2013.
S. E. Holden, Jenkins-Jones, S., Poole, C. D., Morgan, C. L., Coghill, D., and Currie, C. J., The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010), Child Adolesc Psychiatry Ment Health, vol. 7, p. 34, 2013.
C. L. Morgan, Owens, D. R., Aubonnet, P., Carr, E. S., Jenkins-Jones, S., Poole, C. D., and Currie, C. J., Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study, BMJ Open, vol. 3, p. e004025, 2013.
[Page last reviewed 4 November 2019]